目的 研究牛肺泡表面活性劑聯(lián)合大劑量氨溴索治療新生兒呼吸衰竭的療效。方法 選擇2014年1月-2017年12月福建省莆田學(xué)院附屬邵武市立醫(yī)院收治的80例呼吸衰竭新生兒，隨機(jī)分為兩組。對(duì)照組單純給予大劑量（每次7.5 mg，每天4次）的氨溴索，觀察組在對(duì)照組基礎(chǔ)上給予牛肺泡表面活性劑。比較兩組的發(fā)紺消失時(shí)間、呻吟消失時(shí)間、住院時(shí)間、氣促消失時(shí)間和血?dú)庵笜?biāo)。結(jié)果 觀察組有效率為80.00%，明顯高于對(duì)照組的62.50%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。與對(duì)照組比較，觀察組的發(fā)紺消失時(shí)間、呻吟消失時(shí)間、住院時(shí)間和氣促消失時(shí)間均明顯縮短，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的血?dú)庵笜?biāo)（SpO₂、血pCO₂、pH及血pO₂）均明顯改善，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組更為明顯，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組的分泌物阻塞鼻腔、感染和支氣管肺發(fā)育不全發(fā)生率明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 牛肺泡表面活性劑聯(lián)合大劑量氨溴索方案治療新生兒呼吸衰竭的療效明顯優(yōu)于單用氨溴索，且安全性較佳。

Objective To investigate the efficacy of high-dose ambroxol combined with bovine alveolar surfactant in the treatment of neonatal respiratory failure.Methods Selected 80 cases of patients with neonatal respiratory failure who were treated in our hospital from January 2014 to December 2017,divided into two groups randomly.The control group was given high-dose ambroxol alone,while the observation group was given bovine alveolar surfactant.The cyanosis disappeared time,moaning disappeared time,hospitalization time,dyspnea disappearance time and blood gas index were compared between the two groups.Results After treatment,the effective rate of the observation group was significantly higher than control group (P< 0.05).The cyanosis disappeared time,moaning disappeared time,hospitalization time and dyspnea disappearance time in the observation group were significantly shorter than those in the control group (P< 0.05).The blood gas index (SpO₂,blood PaCO₂,pH and blood PaO₂) of the two groups were significantly improved improved after treatment (P< 0.05),and the observation group was more obvious (P< 0.05).The incidence of nasal obstruction,infection and bronchopulmonary dysplasia in the observation group was significantly lower than that in the control group (P< 0.05).Conclusion The efficacy of high-dose ambroxol combined with bovine alveolar surfactant in the treatment of neonatal respiratory failure is significantly better than that of ambroxol alone,and the safety is better.